Makiyama K

ORCID: 0000-0002-7449-2015 · 2 papers in corpus

observational 2026

Fewer Injections and Lower Drug Costs With Long-Acting GnRH Depot Formulations: A Nationwide Analysis of 2.3 Million Patient-Years in Japan

Cancer reports (Hoboken, N.J.) ·doi:10.1002/cnr2.70688

BACKGROUND: Androgen deprivation therapy (ADT) is the base of treatment for prostate cancer, and gonadotropin-releasing hormone (GnRH) drugs are given as depot injections. Long-acting formulations may reduce the number of injections and the…

other 2024

Tissue factor pathway inhibitor 2 (TFPI2) is a potential serum biomarker for clear cell renal carcinoma

Scientific reports ·doi:10.1038/s41598-024-80248-x

Renal and ovarian clear cell carcinoma (CCC) are both characterized by a clear cytoplasm and exhibit similar genomic alterations and clinical characteristics. We hypothesized that both CCCs may share clinical biomarker. Tissue factor pathwa…